中文

科拓生物 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-22
ItemAmountY/Y
Revenue¥0.08B+9.5%
Gross profit¥0.04B
Operating income¥0.02B
Net income¥0.01B-26.5%
Gross margin45.4%Net margin 17.6%
Revenue Q/Q-13.7%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.05B54.6%
R&D¥0.01B10.3%
SG&A¥0.02B18.7%
Tax & other¥0.00B2.4%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

西域旅游锋尚文化美畅股份蓝盾光电卡倍亿南大环境大宏立圣元环保杰美特康泰医学欧陆通回盛生物

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies